Home / Recalls / Novo Nordisk Inc / D-0217-2017

D-0217-2017 Class I Terminated

Recalled by Novo Nordisk Inc — Plainsboro, NJ

Recall Details

Product Type: Drugs
Report Date: December 28, 2016
Initiation Date: September 8, 2016
Termination Date: February 27, 2018
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 71,215 kits

Product Description

GlucaGen HypoKit (glucagon [rDNA origin] for injection), 1 mg per vial, Single use only, Rx Only, Manufactured by: Novo Nordisk A/S 2880 Bagsvaerd, Denmark, NDC 0169-7065-15

Reason for Recall

Defective delivery system: detached needles on the syringe in the kit.

Distribution Pattern

Nationwide and Worldwide

Code Information

Lots: FS6X270, FS6X296, FS6X538, FS6X597, FS6X797, FS6X875; Exp 9/30/2017

Other recalls by Novo Nordisk Inc

D-0245-2026 Class II — Wegovy (semaglutide) Injection, 1 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manuf (December 19, 2025)
D-0244-2026 Class II — Wegovy (semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Man (December 19, 2025)
D-0621-2021 Class I — TRESIBA FlexTouch (insulin degludec injection) 200 units/mL (U-200), 3 mL Prefil (March 22, 2021)
D-0611-2021 Class I — Fiasp FlexTouch (insulin aspart injection) 100 units/mL (U-100), 3 mL Prefilled (March 22, 2021)
D-0614-2021 Class I — Levemir FlexTouch (insulin detemir) injection, 100 units/mL (U-100), 3 mL Prefil (March 22, 2021)
D-0613-2021 Class I — Fiasp (insulin aspart injection), 100 units/mL (U-100), One 10 mL multi-dose via (March 22, 2021)
D-0615-2021 Class I — NovoLog FlexPen (insulin aspart) Injection, 100 units/mL, 3 mL Prefilled Insulin (March 22, 2021)
D-0612-2021 Class I — Fiasp PenFill (insulin aspart injection) 100 units/mL (U-100), 3 mL cartridge, 5 (March 22, 2021)
D-0617-2021 Class II — OZEMPIC (semaglutide) injection, 2 mg/1.5 mL (1.34 mg/mL) Prefilled pen, 1 pen, (March 22, 2021)
D-0618-2021 Class II — Saxenda (liraglutide) Injection, 18 mg/3 mL (6 mg/mL), 1 x 3 mL Prefilled Pen, S (March 22, 2021)